Effectiveness of mRNA COVID-19 Monovalent and Bivalent Vaccine Booster Doses Against Omicron Severe Outcomes Among Adults Aged ≥50 Years in Ontario, Canada: A Canadian Immunization Research Network Study

被引：7
|
作者：
Grewal, Ramandip [1 ,2 ,3 ]
Buchan, Sarah A. [1 ,2 ,3 ,4 ]
Nguyen, Lena [4 ]
Nasreen, Sharifa [2 ,4 ]
Austin, Peter C. [4 ,5 ]
Brown, Kevin A. [1 ,2 ,4 ]
Gubbay, Jonathan [1 ,6 ]
Lee, Nelson [2 ,7 ]
Schwartz, Kevin L. [1 ,2 ,4 ]
Tadrous, Mina [8 ]
Wilson, Kumanan [9 ,10 ,11 ]
Wilson, Sarah E. [1 ,2 ,3 ,4 ]
Kwong, Jeffrey C. [1 ,2 ,3 ,4 ,12 ,13 ]
机构：
[1] Publ Hlth Ontario, Toronto, ON, Canada
[2] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada
[3] Univ Toronto, Ctr Vaccine Preventable Dis, Toronto, ON, Canada
[4] ICES, Toronto, ON, Canada
[5] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada
[6] British Columbia Childrens & Womens Hlth Ctr, Dept Pathol & Lab Med, Vancouver, BC, Canada
[7] Womens Coll Hosp, Inst Hlth Syst Solut & Virtual Care, Toronto, ON, Canada
[8] Univ Toronto, Leslie Dan Fac Pharm, Toronto, ON, Canada
[9] Univ Ottawa, Dept Med, Ottawa, ON, Canada
[10] Ottawa Hosp, Res Inst, Clin Epidemiol Program, Ottawa, ON, Canada
[11] Bruyere Res Inst, Ottawa, ON, Canada
[12] Univ Toronto, Dept Family & Community Med, Toronto, ON, Canada
[13] Univ Hlth Network, Toronto Western Family Hlth Team, Toronto, ON, Canada
来源：
JOURNAL OF INFECTIOUS DISEASES | 2024年 / 229卷 / 02期
基金：
加拿大健康研究院;
关键词：
bivalent; COVID-19; mRNA; vaccine effectiveness; Omicron;
D O I：
10.1093/infdis/jiad419
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
We estimated the effectiveness of booster doses of monovalent and bivalent mRNA COVID-19 vaccines against Omicron-associated severe outcomes among adults aged >= 50 years in Ontario, Canada. Monovalent and bivalent mRNA COVID-19 booster doses provided similar strong initial protection against severe outcomes. Uncertainty remains around waning of protection from these vaccines. Shortly after bivalent mRNA COVID-19 vaccines were introduced, monovalent and bivalent booster doses provided similar strong initial protection against severe outcomes among Ontario community-dwelling adults aged >= 50 years. Uncertainty remains around waning of protection.
引用
收藏
页码：394 / 397
页数：4
相关论文
共 50 条
  • [41] Effectiveness against severe COVID-19 of a seasonal booster dose of bivalent (original/Omicron BA.4-5) mRNA vaccines in persons aged ≥ 60 years: Estimates over calendar time and by time since administration during prevalent circulation of different Omicron subvariants, Italy, 2022-2023-2023
    Fabiani, Massimo
    Mateo-Urdiales, Alberto
    Sacco, Chiara
    Fotakis, Emmanouil Alexandros
    Battilomo, Serena
    Petrone, Daniele
    Del Manso, Martina
    Bella, Antonino
    Riccardo, Flavia
    Stefanelli, Paola
    Palamara, Anna Teresa
    Pezzotti, Patrizio
    VACCINE, 2024, 42 (23)
  • [42] The Advisory Committee on Immunization Practices' Recommendation for Use of Moderna COVID-19 Vaccine in Adults Aged ≥ 18 Years and Considerations for Extended Intervals for Administration of Primary Series Doses of mRNA COVID-19 Vaccines - United States, February 2022
    Wallace, Megan
    Moulia, Danielle
    Blain, Amy E.
    Ricketts, Erin K.
    Minhaj, Faisal S.
    Link-Gelles, Ruth
    Curran, Kathryn G.
    Hadler, Stephen C.
    Asif, Amimah
    Godfrey, Monica
    Hall, Elisha
    Fiore, Anthony
    Meyer, Sarah
    Su, John R.
    Weintraub, Eric
    Oster, Matthew E.
    Shimabukuro, Tom T.
    Campos-Outcalt, Doug
    Morgan, Rebecca L.
    Bell, Beth P.
    Brooks, Oliver
    Talbot, H. Keipp
    Lee, Grace M.
    Daley, Matthew F.
    Oliver, Sara E.
    MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT, 2022, 71 (11): : 416 - 421
  • [43] Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19-Associated Hospitalization Among Immunocompetent Adults Aged ≥65 Years - IVY Network, 18 States, September 8-November 30, 2022
    Surie, Diya
    DeCuir, Jennifer
    Zhu, Yuwei
    Gaglani, Manjusha
    Ginde, Adit A.
    Douin, David J.
    Talbot, H. Keipp
    Casey, Jonathan D.
    Mohr, Nicholas M.
    Zepeski, Anne
    McNeal, Tresa
    Ghamande, Shekhar
    Gibbs, Kevin W.
    Files, D. Clark
    Hager, David N.
    Ali, Harith
    Taghizadeh, Leyla
    Gong, Michelle N.
    Mohamed, Amira
    Johnson, Nicholas J.
    Steingrub, Jay S.
    Peltan, Ithan D.
    Brown, Samuel M.
    Martin, Emily T.
    Khan, Akram
    Bender, William S.
    Duggal, Abhijit
    Wilson, Jennifer G.
    Qadir, Nida
    Chang, Steven Y.
    Mallow, Christopher
    Kwon, Jennie H.
    Exline, Matthew C.
    Lauring, Adam S.
    Shapiro, Nathan I.
    Columbus, Cristie
    Halasa, Natasha
    Chappell, James D.
    Grijalva, Carlos G.
    Rice, Todd W.
    Stubblefield, William B.
    Baughman, Adrienne
    Womack, Kelsey N.
    Rhoads, Jillian P.
    Hart, Kimberly W.
    Swan, Sydney A.
    Lewis, Nathaniel M.
    McMorrow, Meredith L.
    Self, Wesley H.
    MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT, 2022, 71 (51-52): : 1625 - 1630
  • [44] Comparative effectiveness of 3 or 4 doses of mRNA and inactivated whole-virus vaccines against COVID-19 infection, hospitalization and severe outcomes among elderly in Singapore
    Tan, Celine Y.
    Chiew, Calvin J.
    Lee, Vernon J.
    Ong, Benjamin
    Lye, David Chien
    Tan, Kelvin Bryan
    LANCET REGIONAL HEALTH-WESTERN PACIFIC, 2022, 29
  • [45] Second booster doses of adenoviral- and mRNA-based COVID-19 vaccines increase protection against COVID-19 hospitalization: Final analysis from the REFORCO-Brazil real-world effectiveness study during Omicron
    Meeraus, Wilhelmine
    Postema, Abigail
    Gray, Christen M.
    Lee, Andrew
    Santa Maria, Andre
    Furtado, Barbara Emoingt
    Conde-Sousa, Eduardo
    Ouwens, Mario
    Valverde, Douglas Andreas
    Cunha, Clovis Arns da
    Barbosa, Alexandre Naime
    Corte, Claudia
    Taylor, Sylvia
    VACCINE, 2025, 53
  • [46] COVID-19 vaccine booster doses provide increased protection against COVID-19 hospitalization compared with previously vaccinated individuals: Interim findings from the REFORCO-Brazil real-world effectiveness study during Delta and Omicron
    Meeraus, Wilhelmine
    Stuurman, Anke L.
    Durukal, Ilgaz
    Conde-Sousa, Eduardo
    Lee, Andrew
    Santa Maria, Andre
    Furtado, Barbara Emoingt
    Ouwens, Mario
    Gray, Christen M.
    Valverde, Douglas Andreas
    da Silva, Hugo Gomes
    Taylor, Sylvia
    VACCINE, 2023, 41 (42) : 6366 - 6378
  • [47] Relative effectiveness of a heterologous booster dose with adenovirus type 5 vectored COVID-19 vaccine versus three doses of inactivated COVID-19 vaccine in adults during a nationwide outbreak of omicron predominance, in China: a retrospective, individually matched cohort-control study
    Jia, Siyue
    Yin, Zundong
    Pan, Hongxing
    Wang, Fuzhen
    Liu, Xiaoqiang
    Wang, Qing
    Zhang, Li
    Tang, Jihai
    Yang, Hao
    Du, Jiangbo
    Wang, Zhiguo
    Jin, Pengfei
    Peng, Zhihang
    Tang, Rong
    Kang, Guodong
    Wang, Xuewen
    Li, Simin
    Wang, Weixiao
    Li, Jingxin
    Shen, Hongbing
    Zhu, Fengcai
    EMERGING MICROBES & INFECTIONS, 2024, 13 (01)
  • [48] Effectiveness of mRNA BNT162b2 and inactivated CoronaVac vaccines against severe COVID-19 outcomes among non-hospitalised children aged 1-3 years with SARS-CoV-2 Omicron infection
    Wong, Carlos K. H.
    Lau, Kristy T. K.
    Au, Ivan C. H.
    Lau, Eric H. Y.
    Cowling, Benjamin J.
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2024, 63 (03)
  • [49] Monovalent XBB.1.5 COVID-19 vaccine effectiveness against hospitalisations and deaths during the Omicron BA.2.86/JN.1 period among older adults in seven European countries: A VEBIS-EHR network study
    Nunes, Baltazar
    Humphreys, James
    Nicolay, Nathalie
    Braeye, Toon
    Van Evercooren, Izaak
    Hansen, Christian Holm
    Moustsen-Helms, Ida Rask
    Sacco, Chiara
    Fabiani, Massimo
    Castilla, Jesus
    Martinez-Baz, Ivan
    Meijerink, Hinta
    Machado, Ausenda
    Soares, Patricia
    Ljung, Rickard
    Pihlstrom, Nicklas
    Nardone, Anthony
    Bacci, Sabrina
    Monge, Susana
    EXPERT REVIEW OF VACCINES, 2024, 23 (01) : 1085 - 1090
  • [50] Safety Monitoring of COVID-19 mRNA Vaccine First Booster Doses Among Persons Aged ≥12 Years with Presumed Immunocompromise Status - United States, January 12, 2022-March 28, 2022
    Hause, Anne M.
    Baggs, James
    Marquez, Paige
    Abara, Winston E.
    Baumblatt, Jane Gwira
    Thompson, Deborah
    Su, John R.
    Myers, Tanya R.
    Gee, Julianne
    Shimabukuro, Tom T.
    Shay, David K.
    MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT, 2022, 71 (28): : 899 - 903
12345